v3.25.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenue:        
Total revenue $ 27 $ 91 $ 108 $ 164
Operating expenses:        
Cost of revenue 0 18 20 34
Research and development 3,514 4,150 4,995 10,019
General and administrative 2,377 3,314 5,033 6,734
Total operating expenses 5,891 7,482 10,048 16,787
Loss from operations (5,864) (7,391) (9,940) (16,623)
Other income (expense), net:        
Interest income 62 269 143 628
Interest expense (679) (1,282) (1,287) (2,526)
Change in fair value of common stock warrant liabilities (515) 1,568 1,995 259
Change in fair value of derivative liabilities (439) 0 708 0
Change in fair value of Clene Nanomedicine contingent earn-out liability 0 22 0 75
Change in fair value of Initial Stockholders contingent earn-out liability 0 3 0 10
Research and development tax credits and unrestricted grants 16 26 211 312
Total other income (expense), net (1,555) 606 1,770 (1,242)
Net loss before income taxes (7,419) (6,785) (8,170) (17,865)
Income tax expense 0 0 0 0
Net loss (7,419) (6,785) (8,170) (17,865)
Other comprehensive income (loss):        
Unrealized loss on available-for-sale securities 0 2 0 (2)
Foreign currency translation adjustments 63 28 78 (27)
Total other comprehensive income (loss) 63 30 78 (29)
Comprehensive loss $ (7,356) $ (6,755) $ (8,092) $ (17,894)
Net loss per share – basic and diluted (in dollars per share) $ (0.78) $ (1.06) $ (0.89) $ (2.78)
Weighted average common shares used to compute basic and diluted net loss per share (in shares) 9,523,592 6,423,182 9,176,063 6,422,242
Product [Member]        
Revenue:        
Total revenue $ 1 $ 64 $ 65 $ 108
Royalty [Member]        
Revenue:        
Total revenue $ 26 $ 27 $ 43 $ 56